An I-phase Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics of a Single Dose of HEC-151 Injection in Healthy Chinese Participants in a Single-center, Randomized, Placebo (Single-blind) and Positive Control (Open-label) Study
Latest Information Update: 05 Feb 2026
At a glance
- Drugs HEC 151 (Primary) ; Insulin
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
Most Recent Events
- 05 Feb 2026 New trial record